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A B S T R A C T
The aim of this study was to determine the association of bleeding as a complication of warfarin therapy with poly-
morphism of CYP2C9 gene (alleles 1, 2 and 3). The CYP2C9 is the main enzyme for warfarin metabolism. Study inclu-
ded 181 patients receiving warfarin for at least one month. Allele 1 of CYP2C9 gene (in 94.5%) and genotype *1/*1
(57.5%) prevailed. Allele 3 was found in 12.7% patients. Bleeding side-effects occurred in 18 patients (10%). Patients
with allele *1 needed significantly higher maintenance warfarin dose (p=0.011). Those with allele *3 had significantly
lower maintenance warfarin dose (p=0.005) and higher prothrombin time (PT) at induction (p=0.034). Bleeding occur-
red significantly more often in those with lower maintenance warfarin dose (p=0.017). Patients with allele *3 had in-
creased risk of bleeding, with marginal significance (p=0.05). Polymorphism of CYP2C9 could determine dose of warfa-
rin therapy and thus it could be related to the risk of bleeding complications. Allele *3 carriers need lower warfarin dose.
Therefore, initially reduced warfarin induction dose in allele *3 carriers could avoid more prolonged PT and decrease
the risk of bleeding complication.
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Introduction
The pharmacogenetics represents a molecular ground
for drug metabolism on which depend pharmacokinetics
and pharmacodinamics of a certain drug1–3.
The main task of pharmacogenetics is to identify indi-
vidual genetic variations (gene polymorphism) of several
genes which are involved either in drug metabolism or in
drug action through drug related molecules (like en-
zymes, receptors and drug transporters). These genetic
variations may cause metabolic differences after admin-
istration of the standard dose of a drug and this can lead
to more expressed toxicity or treatment failure due to an
altered relation between the dose and the concentration
of the pharmacologically active substance4.
A gene is considered polymorphic if its variation was
present in more than 1% of normal population. Genes are
functionally polymorphic if allelic variants, one or more,
are stable in population, and alter the activity of the
coded protein in comparison with the wild (normal)
type3,5–7.
In the case when pharmacological activity of a drug or
a toxin is associated with catalytic activity of a certain
enzyme, factors influencing the activity of the enzyme
will determine clinical response to the agent. Enzymes
responsible for drugs and activation of other agents and
metabolism express wide interindividual variations in
proteins expression or catalytic activity, thus resulting in
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various fenotypes. Phenotypes are divided into those of
extensive, intermediate, poor and ultraextensive meta-
bolism1,2,8.
The most important oxidative enzymatic system im-
plicated in drugs metabolism is enzymatic superfamily of
cytochrome P450 (CYP). CYP2C9 is one of the four mem-
bers of human CYP2C subfamily (the others are
CYP2C8, CYP2C18, CYP2C19 and CYP2C10 is now con-
sidered a variant of CYP2C9), although genetic analyses
suggest possible existence of three more CYP2C en-
zymes. Cytochromes P450 2C8, 2C9, 2C18 and 2C19
show 82% identical aminoacid sequences, but isoforms
show minor overlap in substrate specificity. Human gene
that codes protein CYP2C9 is located at chromosome
10q24.2 and is greater than 55 kb.
Discovery of 6 different CYP2C9 cDNA sequences en-
couraged many studies of their metabolic activity and
distribution in the population.
The most frequent allele Arg144/Ile359 (CYP2C9*1)
is considered the wild type. Exchange of cytosine with
thymine (C>T) on nucleotide 430 generates Cys144/
Ile359 (CYP2C9*2) allelic variant, and exchange of ade-
nine with cytosine (A>C) on nucleotide 1075 results in
Arg144/Leu359 (CYP2C9*3) allelic variant. T>C on 1076
codes Arg144/Thr359 (CYP2C9*4) allele, C>G on 1080
codes Arg144/Asp360 (CYP2C9*5) allele, and the last dis-
covered null polymorphism (CYP2C9*6) has adenine de-
letion on nucleotide 818. Since CYP2C9*1, *2 and *3
were the first discovered alleles, their in vitro and in vivo
activity has been studied the most thoroughly. These al-
leles make 6 different genotypes: *1/*1 (wild type), *1/*2,
*1/*3, *2/*2, *2/*3 and *3/*3. In vitro studies showed that
CYP2C9*2 and *3 alleles were associated with significan-
tly reduced metabolism of various CYP2C9 substrates in
comparison with the wild type. In vivo studies report
that if there is even only a single allelic variant present,
metabolic activity is significantly reduced. Cytochrome
P450 CYP2C9 metabolizes clinically important drugs
and belongs to the most important enzymes for drugs
metabolism in humans. Substrates for CYP2C9 are fluo-
xetine, losartan, phenitoin, tolbutamid, torsemid, S-war-
farin and non-steroidal anti-inflammatory drugs.
The most used oral anticoagulants are derivatives of
hydroxycumarines and indandion.
Warfarin (Marivarin, Krka, Slovenia), etilbiscumace-
tate (Pelentan, Krka, Slovenia), acenocumarol (Sintrom,
Novartis Pharma, Switzerland), phenprocumon (Mar-
coumar, Roche, Switzerland) belong to derivatives of
hydroxycumarine. Warfarin is the drug of choice. Two
optic isomers of warfarin are in clinical use. Left rotated
(S) warfarin is four times more potent than right rotated
(R) warfarin. Warfarin half-life (t½) is 36–42 h, it is
bound to plasma proteins in circulation, mostly to albu-
min, and it accumulates in liver microsomes. It is predo-
minantly excreted by kidneys in the form of metabolites.
The beginning of action of oral anticoagulants depends
on t½ of coagulation factors: the shortest, 4–6 h, for F
VII, 3 days for F II, 18–30 h for F IX and 2 days for F X.
Therefore, according to some other data, complete anti-
coagulant action to be achieved needs 48–72 hours, even
5–7 days9–12. Warfarin is indicated for treatment and pre-
vention of thromboembolic events. It is used for treat-
ment of venous thrombosis, pulmonary emboli and arte-
rial thrombosis.
Prophylactically it is used for prevention of thrombus
formation in patients with artificial heart valves, with in-
travascular stents, atrial fibrillation, inborn heart valve
errors, patients with history of thromboembolic event,
those with increased risk of thromboembolic event due to
immobilization or surgery, patients with known hyper-
coagulability (antiphospholipid syndrome, protein C or S
deficiency, antithrombin deficiency, factor V Leiden mu-
tation, factor II mutation). There are many contraindica-
tions, mostly relative. Therefore, need for anticoagula-
tion therapy and its risk should be considered for every
patient.
The most frequent side effect of warfarin therapy is
bleeding due to overdosing, interaction with other drugs
or certain condition in a patient. Diseases that increase
the risk of bleeding are gastrointestinal bleeding, cereb-
rovascular diseases, inborn heart errors, hypertension,
atrial fibrillation, myocardial infarction, renal diseases,
liver dysfunction and anemia13–15. Peptic ulcer is surpris-
ingly not related to bleeding during warfarin therapy15.
Nutritional changes (reduced vitamin K intake) and dru-
gs interfering with warfarin metabolism themselves pre-
sent strong risk for bleeding. Two warfarin isomers are
degraded in microsomal liver enzymes by two different
pathways. (S)-warfarin is metabolized more rapidly, but
significant individual variations are possible since enzy-
matic activity is influenced by genetic variations for mic-
rosomal enzymes (CYP polymorphism) and by external
factors. The aim of this study was to determine the asso-
ciation between bleeding as a complication of warfarin
therapy and polymorphism of CYP2C9 gene. We hypoth-
esized that genetic variants for CYP2C9 different from
the wild type carry increased risk for weak warfarin me-
tabolism and consecutive bleeding complications.
Patients and Methods
The study was approved by the Ethical Committee of
University Hospital Osijek.
The inclusion criterion was warfarin therapy for at
least one month. The exclusion criteria were the follow-
ing: treatment with the drugs known to induce or inhibit
elimination of the CYP2C9 substrate (barbiturates, etha-
nol, rifampicin, amiodaron, sulphonamides, fluconasol),
mechanical heart valves, repeated myocardial infarctio-
ns, antiphospholipid syndrome, history of bleeding pre-
ceding warfarin treatment, liver dysfunction.
The study included 181 patients (102 women and 79
men, median age 65 years) who were treated with warfa-
rin for at least a month at the Institute for Transfusion
Medicine University Hospital Osijek. All patients were
Caucasions and from Eastern Slavonia. The participants
signed informed consent.
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The methods of the study were the data collection
from medical records and CYP2C9 genotyping.
The data regarding the patients’ history, warfarin
therapy and bleeding complications were taken from the
medical records, The historical data included demograp-
hic characteristics, underlying illness, check-up prothrom-
bin time (PT) values, warfarin dose and bleeding occur-
rence.
The genotyping of CYP2C9 gene was done at the Clin-
ical Institute for Chemistry of the University Hospital
»Sestre milosrdnice« Zagreb.
Follow-up of anticoagulant therapy was performed by
single-step PT test – Dade Innovin Behring. PT was mea-
sured every 72 hours following the introduction of the
drug, and twice a week for two weeks thereafter (fre-
quency of testing depended on PT stability) and finally
once a month in patients with stable PT. The therapeutic
range of 2.0–3.0 INR was considered optimal.
Cytochrome P450 CYP2C9 genotyping (alleles *1, *2
and *3) was performed by PCR-RFLP (polymerase chain
reaction-restriction fragment length polymorphism). Ge-
notypes of CYP2C9 *1/*1, *1/*2, *1/*3, *2/*2, *2/*3 and
*3/*3 were identified by determination of polymorphism
of length of restriction fragments after digestion of PCR-
-products by restriction endonucleases (AvaII, NsiI, KpnI).
The data were analyzed using standard statistical
methods for descriptive statistics, comparisons and risk
determination. Nonparametric tests were applied due to
small number of patients in certain subgroups. Statisti-
cal analysis was performed by SPSS 10.0 for Windows
statistical program package (J.Scientific, San Rafael, CA,
USA).
Results
Patients’ demographic data, underlying illness and
details concerning warfarin therapy are shown in the ta-
ble 1. Warfarin dose and PT at induction, maintenance
dose and optimal PT, time needed to reach optimal PT
and duration of warfarin therapy were recorded. Gender
was found the confounding factor in respect of warfarin
dose. Men needed significantly higher maintenance war-
farin dose than women (median 4.5 mg, min. 1.1, max.
9.0 vs 3.5 mg, min. 0.3, max. 9.0; z=–2.571, p=0.010,
Mann-Whitney test). The other warfarin therapy param-
eters were not affected by the gender. Patients older than
65 years were not different in warfarin therapy parame-
ters in comparison with those younger. Smoking or alco-
hol consumption did not influence the examined warfa-
rin therapy characteristics.
The patients were divided into two subgroups in res-
pect of bleeding complications of the warfarin therapy.
One hundred and sixty three of the 181 patients did not
have bleeding events (90%), while it occurred in 18 pa-
tients (10%). In 14 patients minor bleeding was recorded
(1 minor hemoptysis or bloody tinged sputum, 6 epis-
taxis, 6 hematomas and 1 microhematuria), while 4 pa-
tients experienced major bleeding (2 melenas and 2 mac-
rohematurias). Minor bleeding was treated by stopping
warfarin only (4 patients), or stopping warfarin was fol-
lowed by vitamin K administration (10 patients). All pa-
tients with major bleeding were hospitalized for median
5 days (min. 3, max. 7) and treated with 20 mg of vitamin
K and with fresh frozen plasma (690 mL in average), or
with erythrocyte transfusion (1200 mL in average) in the
cases of hemoglobin drop of 20 g/L or more. Table 2 pres-
ents distribution of CYP2C9 polymorphisms. Genotype
*1/*1 prevailed (57.5%). There was only one patient ho-
mozygous for *3 (*3/*3). Allele *1 was found in 171 pa-
tient, 58 patients had allele *2 and 23 allele *3. (Table 3).
The two groups of patients formed according to the
bleeding complication of the therapy were compared. In
those older than 65 years of age bleeding was not more
frequent. Male gender and smoking did not carry increa-
sed risk for bleeding, unlike alcohol consumption (OR
4.371, CI 1.213–15.757). In 14 patients who were alcohol
consumers bleeding occurred significantly more often.
That finding rendered alcohol consumption the confoun-
ding variable. (Table 4) The subgroups of patients divi-
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TABLE 1
PATIENTS’ CHARACTERISTICS AND WARFARIN THERAPY
PARAMETERS (N=181)
Characteristic value
Gender (male) (n, %) 79 (43.6)
Age (years) 65 (11–88)*
Age older than 65 years (n, %) 82 (45.3)
Diagnosis
(n, %)
Deep venous thrombosis 58 (32)
Atrial fibrillation 33 (18)
Polytrauma 21 (12)
Stroke 20 (11)
Mitral valve stenosis 17 (9)
Other 32 (18)
Smoking (n, %) 24 (13)
Alcohol consumption (n, %) 14 (8)
Bleeding complication (n, %) 18 (10)
Warfarin dose at induction (mg) 3 (1.5–7.5)*
PT† at induction (INR)§ 1.51 (0.97–8.02)*
Maintenance warfarin dose (mg) 4.11.8‡
PT† at maintenance warfarin
dose – optimal (INR)§ 1.940.28
‡
Time needed to reach optimal PT† (days) 30 (1–450)*
Time of warfarin treatment (months) 5 (1–64)*
*median (minimum-maximum); † prothrombin time; ‡ mean 
SD; §international normalized ratio
TABLE 2
DISTRIBUTION OF CYP2C9 GENOTYPES (N=181)














ded according to the underlying diseases were not signifi-
cantly different in respect of bleeding complication.
Warfarin dose at induction of the therapy did not dif-
fer between those with and those without bleeding com-
plication. However, the group with bleeding had signifi-
cantly higher PT at the therapy induction (median INR
3.64, min. 1, max. 6.2 vs median INR 1.42, min. 1, max.
8.02; z=–3.611, p<0.001, Mann-Whitney test). Never-
theless, those with bleeding complication needed signifi-
cantly lower maintenance dose (median 2.13 mg, min.
0.3, max. 7.5 vs median 4.5 mg, min. 0.6, max. 9.0;
z=–2.376, p=0.017, Mann-Whitney test). Optimal PT at
maintenance dose did not differ between the groups. The
groups did not differ in the time needed to reach the opti-
mal PT and in the duration of the warfarin therapy.(Ta-
ble 5) The lowest recorded optimal warfarin dose was 0.3
mg, and that was the case of the patient with major blee-
ding that occurred in the period of induction. The high-
est optimal warfarin dose was 9.0 mg in two patients
with no bleeding event. Significantly different frequency
bleeding events (Pearsonc2=46.940, p<0.001) was found
between the three subgroups according to PT at induc-
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TABLE 4
RISK FOR BLEEDING COMPLICATIONS IN RESPECT OF
POTENTIAL CONFOUNDING FACTORS (N=181)
OR* CI†
Male gender (n=79) 1.622 0.581–4.532
Older than 65 years (n=82) 2.036 0.751–5.518
Smoking (n=24) 2.043 0.621–6.821
Alcohol consumption (n=14) 4.371 1.213–15.757
* odds ratio; † confidence interval
TABLE 5



















































* median (minimum-maximum); † Mann-Whitney test; ‡ proth-
rombin time; §international normalized ratio
TABLE 3
PATIENTS WITH CYP2C9 ALLELE VARIANTS (N=181)
Allele variant n (%)
*1
171 (94.5)
(n=171, homozygous 104, heterozygous 67)
*2
58 (32)
(n=58, homozygous 5, heterozygous 53)
*3
23 (12.7)
(n=23, homozygous 1, heterozygous 22)
TABLE 6
WARFARIN THERAPY IN RESPECT OF CYP2C9 *1 ALLELE VARIANT (N=181)
Allele *1* Statistics†
Yes (n=171) ‡ No (n=10) z p




































*median (minimum-maximum); † Mann-Whitney test; ‡homozygous 104, heterozygous 67; § prothrombin time; ¶ international normal-
ized ratio
tion of warfarin therapy (INR up to 3.5, between 3.6 and
5.0 and above 5.0). The difference was significant be-
tween patients with INR at induction below 3.6 and in-
termediate INR subgroup (Chi-square=10.242, p=0.017),
and between the patients with INR below 3.6 and those
above 5.0 (c2=46.301, p<0.001). Bleeding occurred in 9
of 163 patients with INR at induction lower than 3.6, in 3
of 9 with intermediate PT and in 6 of 8 patients with PT
above 5.0 INR during the induction period. Four patients
with PT at induction above 5.0 INR and bleeding compli-
cation were homozygous for wild type (*1/*1).
The details concerning warfarin therapy were compa-
red in respect of possession of the certain CYP2C9 allele
variant. Warfarin dose and PT at induction were not dif-
ferent between the patients with and without allele *1.
However, those with allele *1 needed significantly higher
maintenance dose in comparison with the patients with-
out the wild type allele (median 4.5 mg, min. 0.3, max.
9.0 vs median 2.5, min. 0.6, max. 5; z=–2.559, p=0.011,
Mann-Whitney test). They did not differ in optimal PT, in
the time needed to reach it, and in the duration of warfa-
rin therapy. (Table 6) The patients with allele *2 did not
differ from those without allele *2 in the examined de-
tails concerning warfarin therapy. (Table 7) Subgroup of
patients with allele *3 did not differ in induction warfa-
rin dose from those without allele *3, but the therapy
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TABLE 7
WARFARIN THERAPY IN RESPECT OF CYP2C9 *2 ALLELE VARIANT (N=181)
Allele *2* Statistics†
Yes (n=58) ‡ No (n=123) z p






























* median (minimum-maximum); † Mann-Whitney test; ‡homozygous 5, heterozygous 53; §prothrombin time; ¶ international normali-
zed ratio
TABLE 8
WARFARIN THERAPY IN RESPECT OF CYP2C9 *3 ALLELE VARIANT (N=181)
Allele *3* Statistics†
Yes (n=23)‡ No (n=158) z p






























* median (minimum-maximum); † Mann-Whitney test; ‡homozygous 1, heterozygous 22; §prothrombin time; ¶ international normali-
zed ratio
produced significantly more prolonged PT at induction
in those having the allele in question (median INR 2,
min. 1.02, max. 7.3 vs median 1.44, min. 0.97, max. 8.02;
z=–2.116, p=0.034, Mann-Whitney test). Patients with
allele *3 also needed lower warfarin maintenance dose
than the patients without the allele (median 3 mg, min.
0.3, max. 6.5 vs median 4.5 mg, min. 0.6, max. 9; z=
–2.790, p=0.005). The patients with allele *3 did not dif-
fer in optimal PT, time needed to reach it and in the du-
ration of the warfarin therapy from those without that
allele. (Table 8)
Subgroups of patients according to the CYP2C9 geno-
type were compared in respect of warfarin therapy. The 6
subgroups did not differ in warfarin dose at induction
and in the PT reached by that initial therapy. However,
they did differ significantly in the warfarin dose needed
to maintain optimal PT (c2 =12.854, p=0.025, Kruska-
l-Wallis test). Genotype *3/*3 was excused from post hoc
analysis, while there was only one patient in the sub-
group. Post hoc Mann-Whitney test found the significant
difference between genotypes *1/*1 and *1/*3 (4.5 mg,
min. 1.1, max. 9.0 vs 3 mg, min. 0.3, max. 6.5; z=–2.309,
p=0.021). The 6 subgroups did not differ in the optimal
PT, time needed to reach it and in the duration of warfa-
rin therapy. (Table 9)
Table 10 shows the distribution of bleeding events in
the subgroups formed according to the CYP2C9 geno-
type.
The study examined the risk for bleeding complica-
tion of warfarin therapy in the presence of certain
CYP2C9 allele. Only marginal significance was found for
the increased risk carrying by allele *3 (c2=4.511, p=0.05).
(Table 11).
The three subgroups of patients, as divided according to
the bleeding occurrence, were not different considering
the underlying diagnosis (Pearson c2= 25.581, p=0.375).
Discussion
Genetic variability in response to drugs between indi-
viduals is currently of a great scientific interest consider-
ing the important therapeutically consequences.
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TABLE 9
















































































*prothrombin time; †international normalized ratio; ‡c2=12.854, p=0.025, Kruskal-Wallis H test; post hoc *1/*1 vs *1/*3 z=–2.309,
p=0.021, Mann-Whitney test; §median (minimum-maximum)
TABLE 10















n (%) 12 1 4 0 1 0
TABLE 11
RISK FOR BLEEDING COMPLICATION IN RESPECT OF














*odds ratio; † confidence interval; ‡c2=4.511, p=0.05
Enzymatic family P450 (CYP) is the most important
system implicated in biotransformation of drugs and
other xenobiotics in humans. Enzymes CYP2C9, CYP2C19,
CYP2D6 and CYP3A4 are responsible for oxidative meta-
bolism of more than 90% currently used drugs. Warfarin
is the most frequently prescribed anticoagulant in Eu-
rope and North America16,17,18. CYP2C9 is the main en-
zyme responsible for warfarin metabolism. Beside the
wild type of the allele (CYP2C9*1), there are two another
allelic variants (CYP2C9*2 and *3) identified, which re-
sulted from point mutations of CYP2C9 gene19. Higashi20
reports that the alleles *2 and *3 cause 30% and 80% re-
duction in enzymatic activity, respectively, as compared
with the wild type. According to Aithal21 the allele *2 has
12% of the activity of the wild type, and the allele *3 less
than 5% of the same. Meyer3 reports data on 0.2–1.0% of
Caucasians being CYP2C9 weak metabolizers (homozy-
gous or heterozygous for alleles *2 and *3), and on
14.0–37.0% Caucasians heterozygotes for CYP2C9 *2
and *3, the feature responsible for reduced enzymatic ac-
tivity. In comparison with the cited paper our patients
(all Caucasions from Eastern Slavonia) were homozy-
gous for allele *1 in quiet less proportion (57.5%), whe-
reas so-called weak metabolizers were more frequent
(42.5% homozygotes or heterozygotes for alleles *2 and
*3). All pharmacogenetic studies point out that ethnic or-
igin should be considered by investigating pharmacoge-
netic distinctions and pharmacotherapy. Identification
of CYP2C9 genotype prior to warfarin therapy initiation
is an example of benefit of the applied pharmacogenetics
in routine daily practice.
Taube and al.22, Scordo and al.23, Wittkovsky24, Free-
man25, Haining26, Takashi27, Ingelman-Sundberg7, Ogg28,
Aithal21 and other authors report on genetic polymor-
phism of CYP2C9 resulting in variants *2 and *3, which
have reduced catalytic activity in S-warfarin metabolism
in comparison with the wild type.
Aithal and al.21 studied polymorphism of CYP2C9 in
regard with warfarin dose and risk for bleeding complica-
tion of the treatment in Great Britain in 36 patients re-
ceiving 1.5 mg of warfarin, 52 patients receiving stan-
dard dose and in 100 healthy controls. They report on the
lack of significant difference in CYP2C9 genotype distri-
bution between healthy controls and patients on stan-
dard dose.
While in patients with *1/*2 genotype optimal warfa-
rin dose was by 20% reduced in comparison with the wild
type carriers needs, CYP2C9*3 mutation, even in hetero-
zygotes, showed an excellent relation of in vitro and in
vivo results in the sense of reduced warfarin metabolism
and reduced optimal dose needed. Wild type allele *1 car-
riers in our study needed higher warfarin dose to main-
tain optimal PT, whereas carriers of allele *3 required
lower maintenance dose. Standard induction dose in al-
lele *3 carriers led to more prolonged PT. These findings
are in concordance with presumably reduced warfarin
metabolism with CYP2C9 allele variants other than wild
type.
Genetic polymorphism of CYP2C9, allele *3 and allele
*2, is associated with an increased risk of an extreme an-
ticoagulant response by the time of the induction of the
therapy and bleeding complication3,21,27,29,30.
Landefeld and Beyth reported on annual incidence of
bleeding based on the data gathered from literature: fa-
tal 0.6%, severe 3.0% and weak 9.6%. They cite the four
independent risk factors for severe bleeding: age over 65,
history of stroke and gastrointestinal bleeding, and 1 or
more concomitant diseases beside the main disease14.
Age over 65 was not associated with the risk of bleed-
ing in our patients, even though they were in significant
proportion over 65 years of age (45,3%). History of stroke
did not increase the risk for bleeding in our patients.
However, we found increased risk for bleeding in alcohol
consumers.
Aithal21 reports on the association of bleeding inci-
dence with warfarin therapy with the intensity of antico-
agulant therapy and prothrombin time deviation. In our
patients bleeding occurred more often in those with more
prolonged PT at induction and in patients requiring
lower maintenance dose. Thus, our finding confirms the
association found in the cited report. The lowest mainte-
nance warfarin dose in our study was 0.30 mg, and it was
in the case of a patient who experienced major bleeding
during the induction of the therapy. The risk of bleeding
is higher at the beginning of the treatment. Several stud-
ies showed that the relative risk for bleeding rose with
the duration of the drug therapy, while the other authors
reported on a higher risk for bleeding during the first 90
days after the therapy was stabilized once9. When divi-
ded in respect of bleeding complication, our patients did
not differ in the duration of warfarin therapy. They were
not different concerning the time needed to achieve opti-
mal PT. These findings suggest that warfarin dose and
effect on PT have more important role for bleeding com-
plications than the treatment time variables.
Ogg and al.28 describe bleeding complications in two
patients homozygous for allele *3 during introduction of
warfarin therapy. In our study only one patient was
homozygote for allele *3, with optimal daily warfarin
dose of 1.5 mg, and did not experience bleeding complica-
tion. This could be explained by frequent and careful
prothrombin time control and precise warfarin dose ad-
justment, but having only one patient certainly limits
the conclusions.
The subgroups of patients divided according to INR at
induction differed significantly regarding the bleeding
complication of warfarin therapy (Pearson Chi-square =
46.940, p<0.001). Bleeding was more common in those
with higher INR values. Palareti reports on higher risk of
bleeding with INR above 4.5, and the exponential incre-
ment of that risk with INR above 5.014. Our data suggest
that INR above 3.5 significantly increase the likelihood
for bleeding side-effect.
The patients divided according to the underlying ill-
ness did not differ significantly in the frequency of bleed-
ing complications.
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Our survey is the first study of CYP2C9 gene poly-
morphism in the population of Eastern Croatia. The ulti-
mate goal of pharmacogenetic polymorphism investiga-
tions is to create pharmacogenetic identification card for
each patient. CYP2C9 alleles 2* and 3* are known as
weak metabolizers. Our findings support the presumable
hypothesis. Identifying allele *3 carriers could enable re-
ducing warfarin dose at induction, thus avoiding extreme
PT prolongation with standard dose and decreasing the
risk of bleeding complication. However, bleeding occurs
in the wild type CYP2C9 carriers, too. Actually, if one ex-
cludes relative proportions most of the patients with
bleeding carried CYP2C9*1/*1 genotype, which indicated
the possibility of the existence of another CYP2C9 vari-
ants in the same patients that were not identified by the
available laboratory methods.
Therefore, careful titration of warfarin dose and regu-
lar PT check-ups are priorities in warfarin therapy moni-
toring. CYP2C9 genotype seems to be not the only deter-
minant of the clinical response to warfarin therapy and
bleeding side-effects. According to our findings gender
and alcohol consumption deserve some attention.
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POVEZANOST POLIMORFIZMA GENA ZA CYP2C9 I KRVARENJA NASTALOG KAO
KOMPLIKACIJA TERAPIJE VARFARINOM
S A @ E T A K
Cilj istra`ivanja bio je odrediti povezanost krvarenja kao komplikacije lije~enja varfarinom i polimorfizma gena za
CYP2C9 (aleli 1, 2 i 3). CYP2C9 je glavni enzim u metabolizmu varfarina. U istra`ivanje je uklju~en 181 bolesnik lije~en
varfarinom najmanje 1 mjesec. Na|ena je najve}a u~estalost alela 1 gena za CYP2C9 (u 94,5%) i genotipa *1/*1 (57,5%).
Alel 3 je na|en u 12,7% bolesnika. Krvarenje se pojavilo u 18 bolesnika (10%). Ispitanicima koji su imali alel *1 trebala
zna~ajno je ve}a doza odr`avanja varfarina (p=0,011). Nositelji alela *3 su trebali zna~ajno manju dozu odr`avanja var-
farina (p=0,005) a dulje protombinsko vrijeme (PT) uz indukcijsku terapiju (p=0,034). Krvarenje se javilo ~e{}e u oso-
ba s manjom potrebnom dozom odr`avanja varfarina (p=0,017). Nositelji alela *3 imali su povi{en rizik krvarenja, s
grani~nom statisti~kom zna~ajno{}u (p=0,05). Polimorfizam gena za CYP2C9 povezan je s potrebnom dozom varfarina
i posljedi~nim rizikom krvarenja kao komplikacije te terapije. Posjedovanje alela *3 zahtijeva manju dozu varfarina.
Stoga bi se smanjenjem induktivne doze varfarina u nositelja alela *3 moglo izbje}i prekomjerno produljenje PT i sma-
njiti rizik komplikacija krvarenja.
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